FSA
ATRA icon

Franklin Street Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Franklin Street Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,232
Closed -$633K – 155
2017
Q1 		$633K Buy
1,232
+800
+185% +$331K 0.11% 100
2016
Q4 		$153K Buy
432
+32
+8% +$13.5K 0.03% 162
2016
Q3 		$214K Buy
+400
New +$217K 0.04% 168

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Franklin Street Advisors's ATRA Position: Q2 2017 in Review

Franklin Street Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2017, closing a stake of 1,232 shares — an estimated $633K sold.

Franklin Street Advisors first reported a position in ATRA in Q3 2016 and held it in 3 quarters. The position peaked at $633K in Q1 2017. 85 funds tracked by Wall St. Rank hold ATRA as of Q2 2017.

  • Franklin Street Advisors reported no remaining Atara Biotherapeutics position as of Q2 2017 after selling out during the quarter.
  • Franklin Street Advisors sold 1,232 Atara Biotherapeutics shares in Q2 2017, an estimated $633K.
  • Franklin Street Advisors first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 3 quarters.
  • Franklin Street Advisors's Atara Biotherapeutics position peaked at $633K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2017.

Based on Franklin Street Advisors's 13F filing for Q2 2017, filed 13 Jul 2017.